Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06889753

A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.

The goal of this study is to investigate the effect of pollen extracts on menopausal symptoms in healthy women The main question it aims to answer is:

What is the difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex Water Soluble Pollen Extract (WSPE), Lipid Soluble Pollen Extract (LSPE), and Placebo?

Participants will be asked to complete the MRS assessment tool to rate their menopausal symptoms while receiving either WSPE, LSPE, or Placebo.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Menopausal Women

Age range

45 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

KGK Science Inc.

London, Ontario, N6B3L1, Canada

Location status: Recruiting

Location contact

David Crowley, MD

PRINCIPAL_INVESTIGATOR

Erin Lewis, PhD

CONTACT

[email protected]

2262424551 ext. 248

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females between 45-60 years of age, inclusive
  • BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive
  • Self-reported menopausal women who have not had a menstrual period for >12 months prior to screening and are experiencing at least moderate menopausal symptoms as assessed by the total MRS score of ≥9 at screening
  • Presence of menopausal symptoms for at least six months prior to screening including, vasomotor symptoms (hot flushes, sweating) AND at least two of the following symptoms: sleep disturbance, joint pain, mood changes, fatigue and lack of energy, vaginal dryness, urinary changes, and changes in sexual function
  • Agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, medications, dietary supplements, and sleep
  • Able and willing to complete all study assessments
  • Provided voluntary, written, informed consent to participate in the study
  • Healthy as determined by medical history with no unstable, diagnosed medical conditions as assessed by the Qualified Investigator (QI)

Exclusion criteria

  • Females who have had unilateral oophorectomy or hysterectomy or uterine ablation
  • Allergy (including bee products or pollen, sensitivity, or intolerance to investigational products or placebo ingredients
  • Ongoing diagnosis with anxiety disorder, sleep disorder, or major depression as assessed by the QI
  • Ongoing unstable diagnosis of musculoskeletal disorders as assessed by the QI
  • Current untreated urogenital diagnosis as assessed by the QI
  • Unstable metabolic disease or chronic diseases as assessed by the QI
  • Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
  • Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  • Current unstable Type I or Type II diabetes
  • Significant cardiovascular event in the past six months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  • History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  • Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least three months will be considered by the QI
  • Major surgery in the past three months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  • Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years
  • after diagnosis are acceptable
  • Individuals with unstable autoimmune disease or are immune compromised as assessed by the QI
  • Use of medical cannabinoid products
  • Chronic use of cannabinoid products (>2 times/week) as assessed by the QI
  • Alcohol intake average of >2 standard drinks per day as assessed by the QI
  • Alcohol or drug abuse within the last 12 months
  • Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
  • Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
  • Individuals who are unable to give informed consent
  • Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
  • Asthmatic, as assessed by the QI

Treatment and study plan

Graminex WSPE

Dietary Supplement

Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.

Graminex LSPE

Dietary Supplement

Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.

Placebo

Dietary Supplement

Placebo

Primary outcomes

  1. The difference in change in severity of menopausal symptomsbaseline at Week 36 between Graminex WSPE, Graminex LSPE, and Placebo

    Time frame: Week 0 (baseline) to 36

    The difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex WSPE, Graminex LSPE, and Placebo.

Secondary outcomes

  1. The difference in change in severity of menopausal symptoms from baseline at Week 6 between Graminex WSPE, Graminex LSPE, and Placebo

    Time frame: Week 0 (baseline) to 6

    The difference in change in severity of menopausal symptoms as assessed by total MRS score from baseline at Week 6 between Graminex WSPE, Graminex LSPE, and Placebo.

  2. The difference in change in severity of menopausal symptoms from baseline at Week 12 between Graminex WSPE, Graminex LSPE, and Placebo

    Time frame: Week 0 (baseline) to 12

    The difference in change in severity of menopausal symptoms as assessed by total MRS score from baseline at Week 12 between Graminex WSPE, Graminex LSPE, and Placebo.

  3. The difference in change in severity of menopausal symptoms from baseline at Week 24 between Graminex WSPE, Graminex LSPE, and Placebo

    Time frame: Week 0 (baseline) to 24

    The difference in change in severity of menopausal symptoms as assessed by total MRS score from baseline at Week 24 between Graminex WSPE, Graminex LSPE, and Placebo.

  4. The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6

    Time frame: Week 0 (baseline) to 6

    The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6.

  5. The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12

    Time frame: Week 0 (baseline) to 12

    The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12.

  6. The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24

    Time frame: Week 0 (baseline) to 24

    The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24.

  7. The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36

    Time frame: Week 0 (baseline) to 36

    The difference in change in scores of individual domains of the MRS including Somatic, Psychological, and Urogenital domains between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36.

  8. The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6

    Time frame: Week 0 (baseline) to 6

    The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6.

  9. The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12

    Time frame: Week 0 (baseline) to 12

    The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12.

  10. The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24.

    Time frame: Week 0 (baseline) to 24

    The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24.

  11. The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36

    Time frame: Week 0 (baseline) to 36

    The difference in change in scores of individual symptoms included in the MRS between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36

  12. The difference in change in sleep disturbance between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6

    Time frame: Week 0 (baseline) to 6

    The difference in change in sleep disturbance as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance form 8b between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 6

  13. The difference in change in sleep disturbance between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12

    Time frame: Week 0 (baseline) to 12

    The difference in change in sleep disturbance as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance form 8b between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 12.

  14. The difference in change in sleep disturbance between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24

    Time frame: Week 0 (baseline) to 24

    The difference in change in sleep disturbance as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance form 8b between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 24.

  15. The difference in change in sleep disturbance between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36

    Time frame: Week 0 (baseline) to 36

    The difference in change in sleep disturbance as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance form 8b between Graminex WSPE, Graminex LSPE, and Placebo from baseline at Week 36.

Other outcomes

  1. Incidence of post-emergent adverse events (AE)

    Time frame: Week 0 (baseline) to 36

    Incidence of post-emergent adverse events (AE)

  2. Clinically relevant changes in blood pressure (BP) after supplementation

    Time frame: Week 0 (baseline) to 36

    Clinically relevant changes in blood pressure (BP) after supplementation with WPSE

  3. Clinically relevant changes in blood pressure (BP) after supplementation

    Time frame: Week 0 (baseline) to 36

    Clinically relevant changes in blood pressure (BP) after supplementation with LPSE

  4. Clinically relevant changes in heart rate (HR) after supplementation

    Time frame: Week 0 (baseline) to 36

    Clinically relevant changes in heart rate (HR) after supplementation with WSPE

  5. Clinically relevant changes in heart rate (HR) after supplementation

    Time frame: Week 0 (baseline) to 36

    Clinically relevant changes in heart rate (HR) after supplementation with LSPE

Study contacts

Contact information is provided by the study sponsor or research team.

Erin Lewiss, PhD

CONTACT

[email protected]

1-226-242-4551 ext. 248

Sponsors and collaborators

Lead sponsor

Graminex LLC

Other

Collaborators

  • KGK Science Inc.

Registry information

Official study title

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 21, 2025
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.